NCT06193928 - Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

September 20, 2028

Study Completion Date

September 20, 2030

Conditions

Alagille SyndromeProgressive Familial Intrahepatic Cholestasis

Interventions

DRUG

Livmarli

The recommended dosage is 380 mcg/kg once daily.

DRUG

Livmarli

The recommended dosage us 570 mcg/kg twice daily.

Trial Locations (8)

15260

RECRUITING

Children Hospital of Pittsburgh, Pittsburgh

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

30322

RECRUITING

Children's Healthcare of Atlanta - Emory University School of Medicine, Atlanta

64108

RECRUITING

Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology, Kansas City

80045

RECRUITING

Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado, Aurora

84112

RECRUITING

University of Utah, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Salt Lake City

90027

RECRUITING

Children's Hospital Los Angeles CHLA, Los Angeles

97239

RECRUITING

Oregon Health and Science University, Division of Pediatric Gastroenterology, Department of Pediatrics, Portland